Literature DB >> 12716369

Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study.

Maher K Gandhi1, Sarath Lekamwasam, Ingrid Inman, Stephen Kaptoge, Lorraine Sizer, Shirley Love, Philip W Bearcroft, Thomas P Milligan, Christopher P Price, Robert E Marcus, Juliet E Compston.   

Abstract

Reduced bone mineral density (BMD) has been reported following allogeneic stem cell transplantation (alloSCT) but the effects of autologous SCT (autoSCT) are less well characterized. We performed a prospective study of BMD changes and its determinants in 44 SCT recipients (38 auto and six allo; 30 peripheral blood SCT and 14 bone marrow transplantation). Serial measurements of BMD at the lumbar spine and femoral neck were performed at baseline and at 3, 6, 12 and 24 months, and spinal radiographs were performed at baseline and 12 months. Mean baseline BMD values at the femoral neck and spine were within normal limits. At 3 months, there was a significant decline of BMD at the femoral neck (P = 0.011) and a non-significant trend towards reduction at the spine. BMD loss persisted for up to 2 years at the femoral neck (P = 0.005), but values returned to baseline at the spine. Reflecting the rapid initial decline in BMD, bone-specific alkaline phosphatase (a serum marker of bone formation) showed a significant initial decline at 1 month but had recovered to pretransplant levels by 3 months. No new fractures were detected at 1 year post transplant. Sex, diagnosis, use of total body irradiation, stem cell source and type of graft (auto versus allo) did not significantly predict BMD change over the first 12 months. In conclusion, significant and persistent bone loss at the femoral neck was demonstrated in this group of patients following stem cell transplantation. The implications of these findings for future fracture risk require further study.

Entities:  

Mesh:

Year:  2003        PMID: 12716369     DOI: 10.1046/j.1365-2141.2003.04303.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Bone mass and microarchitecture of irradiated and bone marrow-transplanted mice: influences of the donor strain.

Authors:  A Dumas; M Brigitte; M F Moreau; F Chrétien; M F Baslé; D Chappard
Journal:  Osteoporos Int       Date:  2008-06-12       Impact factor: 4.507

Review 2.  Cancer therapies and bone health.

Authors:  Mimi I Hu; Huifang Lu; Robert F Gagel
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

3.  Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.

Authors:  Huifang Lu; Richard E Champlin; Uday Popat; Xerxes Pundole; Carmelita P Escalante; Xuemei Wang; Wei Qiao; William A Murphy; Robert F Gagel
Journal:  Bonekey Rep       Date:  2016-10-19

Review 4.  Bone management in hematologic stem cell transplant recipients.

Authors:  D L Kendler; J J Body; M L Brandi; R Broady; J Cannata-Andia; M J Cannata-Ortiz; A El Maghraoui; G Guglielmi; P Hadji; D D Pierroz; T J de Villiers; R Rizzoli; P R Ebeling
Journal:  Osteoporos Int       Date:  2018-09-03       Impact factor: 4.507

Review 5.  Transplantation osteoporosis.

Authors:  Peter R Ebeling
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

6.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

7.  Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.

Authors:  Navneet S Majhail; Kirsten K Ness; Linda J Burns; Can-Lan Sun; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-20       Impact factor: 5.742

8.  Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors.

Authors:  P Anandi; N A Jain; X Tian; C O Wu; P A Pophali; E Koklanaris; S Ito; B N Savani; J Barrett; M Battiwalla
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

9.  Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.

Authors:  Andreas Hausmann; Wolfgang Hill; Hans Joachim Stemmler; Georg Ledderose; Andrea Baur-Melnyk; Susanne Fritsch; Johanna Ullmann; Hans-Jochem Kolb; Sandra Geiger; Johanna Tischer
Journal:  Chemother Res Pract       Date:  2012-04-10

10.  Impact of denosumab on bone mass in cancer patients.

Authors:  Ursa Brown-Glaberman; Alison T Stopeck
Journal:  Clin Pharmacol       Date:  2013-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.